BIIB

#421
Biogen Inc. - Common Stock
196.0 0 USD
-0.74%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
196.00
196.06
Rango anual
121.06
205.97
Cambio diario
-0.74%
Variación mensual
+1.01%
Variación en los últimos 6 meses
+8.80%
Cambio anual
+48.70%
Cierres anteriores
197.4 7
Open
196.0 6
Mínimo
196.0 0
High
196.0 6
Volumen
265
Ver el calendario completo Full chart

Financials

Visión general Informes Estadísticas
Trimestre Año
Informe de resultados Saldo Flujo de caja
Valor Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26 TTM

Biogen Inc. - Common Stock

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.

Noticias